Use of peg-ifn-alpha and ribavirin for the treatment of...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 47/48 (2006.01) A61K 31/7056 (2006.01) A61P 31/14 (2006.01) A61K 38/21 (2006.01)

Patent

CA 2334267

The present invention provides the use of PEG-IFN-.alpha. conjugates in association with Ribavirin for the manufacture of medicaments for the treatment of chronic hepatitis C infections. The present invention also provides a method for treating chronic hepatitis C infections in patients in need of such treating comprising administering an amount of PEG- IFN-.alpha. conjugate in association with an amount of Ribavirin effective to treat hepatitis C.

La présente invention concerne l'utilisation de conjugués PEG-IFN- alpha , en association avec la ribavirine, pour fabriquer des médicaments destinés à traiter les infections chroniques par le virus de l'hépatite C. La présente invention concerne également une méthode permettant de traiter les infections chroniques par le virus de l'hépatite C chez des patients nécessitant un tel traitement, ces méthodes consistant à administrer une quantité d'un conjugué PEG-IFN- alpha en association avec une quantité de ribavirine efficace pour traiter l'hépatite C.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of peg-ifn-alpha and ribavirin for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of peg-ifn-alpha and ribavirin for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of peg-ifn-alpha and ribavirin for the treatment of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1766739

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.